For more information on pursuing trade policy interests through the legislative process, please contact Nicole Bivens Collinson at (202) 730-4956 or via email.
Trade Remedies. The China Trade Cheating Restitution Act (H.R. 6254, introduced Dec. 13 by Reps. Panetta, D-Calif., and Valadao, R-Calif.) would ensure that U.S. Customs and Border Protection distributes antidumping duties to U.S. garlic, honey, and crawfish producers that weren’t paid between 2000 and 2014 under the Continued Dumping and Subsidy Offset Act.
H.R. 6330 (introduced Dec. 20 by Rep. Higgins, D-N.Y.) would amend the Tariff Act of 1930 to provide for consideration of the effect of excess production capacity in nonmarket economy countries to determine threat of material injury to U.S. industry in antidumping and countervailing duty investigations.
Exports. The Continuing Robust and Uninhibited Drilling and Exporting Act (H.R. 6259, introduced Dec. 14 by Rep. Arrington, R-Texas) would restrict the president’s ability to ban exports of crude oil without first providing a credible national security risk.
Supply Chains. H.R. 6309 (introduced Dec. 16 by Rep. Kinzinger, R-Ill.) would establish a U.S. strategy to counter threats to supply chains for critical goods.
The National Critical Capabilities Defense Act (H.R. 6329, introduced Dec. 20 by Rep. DeLauro, D-Conn.) would create a whole-of-government screening process for outbound investments and the offshoring of critical capacities and supply chains to ensure that the U.S. can quickly detect supply chain vulnerabilities.
Drugs. The Anyone But China Safe Drugs Act (S. 3401, introduced Dec. 15 by Sen. Cotton, R-Ark.) would (1) require the Food and Drug Administration to create a registry of all drugs and corresponding active pharmaceutical ingredients that are produced outside the U.S. and are determined to be critical to the health and safety of Americans, (2) require all federally qualified health facilities to purchase pharmaceutical products that have no APIs produced in China (to be phased in over two years), and (3) require drug companies to list the APIs and their countries of origin on the labels of imported and domestically produced finished drug products.
Copyright © 2022 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.